(MENAFN- EIN Presswire) EINPresswire/ -- Vidac Pharma Holdings Plc., a clinical-stage oncology company pioneering first-in-class therapies targeting the unique metabolism of cancer cells, is pleased to announce that Sphene Capital, the highly respected European independent analyst house, has once again issued a“Buy” recommendation for Vidac Pharma's shares. The reaffirmed rating comes with no change in the analyst's GBP-based valuation of the Company. The target price has been adjusted slightly from €4.20 to €4.10 per share, reflecting currency movements between the British Pound and Euro, while maintaining confidence in the Company's long-term value.

This renewed“Buy” recommendation follows the recent regulatory authorization in Germany to initiate Vidac Pharma's new Phase 2 clinical study in actinic keratosis (AK), focusing specifically on highly proliferative lesions-a clinically significant patient segment with considerable unmet need.

Dr. Max Herzberg, Founder and CEO of Vidac Pharma, commented:
“We are proud that a high-quality analyst group such as Sphene Capital, through their understanding of our science, recognizes the importance of this new claim for our future market positioning. Their continued confidence highlights the clear direction of our program as we move toward a Phase 3 trial.”

Vidac Pharma remains committed to advancing its innovative Tuvatexib (VDA-1102) platform as it continues to develop first-in-class therapies addressing the abnormal metabolic pathways of cancer and pre-cancerous skin lesions.
To read the complete Sphene Capital analysis, please click the link

MENAFN21112025003118003196ID1110377939